Anti-Viral Drug Therapy Market - By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza), Anti-Viral Drug Therapy Market Size, Opportunities And Strategies - Global Anti-Viral Drug Therapy Market Forecast To 2030

Starting Price : $4000.00 | Pages : 258 | Published : November 2020 | | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN

Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin.

Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Anti-Viral Drug Therapy Market Size

The global anti-viral drug therapy market reached a value of nearly $46,456.4 million in 2019, having increased at a compound annual growth rate (CAGR) of 5.0% since 2015. The market is expected to grow from $46,456.4 million in 2019 to $ 61,571.9 million in 2020 at a rate of 32.5%. The growth is mainly due to the increase in number of COVID-19 cases. The market is then expected to grow at a CAGR of 8.3% from 2021 and reach $74,385.9 million in 2023. The market is expected to reach $ 87,230.5 million in 2025, and $ 130,125.3 million in 2030.

Growth in the historic period resulted from rise in incidence of viral diseases, rapid growth in elderly population and strong economic growth. Factors that negatively affected growth of the market include patent expiration and increased pricing pressures. Going forward, rising number of COVID-19 cases and development of drug discovery procedures will positively affect the market. Factors that could hinder the growth of the anti-viral drug therapy market in the future include COVID-19 pandemic and shortage of supply of anti-viral drugs.

Anti-Viral Drug Therapy Market Drivers

The key drivers of the anti-viral drug therapy market include:  

Developments In Drug Discovery Procedures

The anti-viral drug therapy market is expected to benefit from the latest developments in drug discovery procedures such as stem cells and organ-on-chip (OOC) technologies. OOCs are micro-engineered biometric systems that simulate the activities, mechanics and physiological responses of organ systems. Drug trial processes such as target identification, validation, and screening are being executed through OOC and stem cell technologies. These technologies are considerably reducing the drug discovery costs and generating reliable predictions on drug efficiency and human safety. Another area of development is physiology-simulation modelling, in which the integrated physiology of the human organism, in both health and disease, is simulated through a computer program. Eli Lilly and Pfizer have adopted Amazon’s Elastic Compute Cloud (EC2) platform to conduct simulation models in early stages of the drug discovery process that are operational within hours, whereas traditional models take weeks to conduct simulations. The wide adoption of these technologies is expected to drive the anti-viral drug therapy market in the forecast period.

Anti-Viral Drug Therapy Market Restraints

The key restraints on the anti-viral drug therapy market include:

Supply Shortages Of Anti-Viral Drugs  

Due to COVID-19 pandemic, there are shortages in supply of anti-viral drugs which is expected to restrain the market in the forecast period. As there are no particular drugs available to treat COVID-19, doctors and physicians are prescribing existing anti-viral drugs in the treatment of COVID-19. Anti-viral drug supply shortage aroused due to a drastic increase in the number of COVID-19 cases across the world. For instance, in July 2020, there was a shortage of the Remdesivir drug which is an antiviral drug?developed by Gilead Sciences Inc and was in high demand for the treatment of COVID-19.

Anti-Viral Drug Therapy Market Trends

Major trends influencing the anti-viral drug therapy market include:

Combination Drug Therapy For Viral Diseases

Companies in the anti-viral drug therapy market are increasingly focusing on development and launch of combination drug therapy for treating HIV and other viral infections. Combination therapy involves the formulation of different drugs for treating different diseases. Combination therapy for treating viral infections has been proved effective in suppressing the replication of viruses and reducing antiviral resistance. In December 2019, Hetero, an India based pharmaceutical company launched an anti-retroviral combination drug consisting combination of drugs including Bictegravir (50mg), Emtricitabine (200mg), and Tenofovir Alafenamide (25mg) for treating patients with HIV. Also, in May 2020, a combination drug dose of Lopinavir/ritonavir which is already approved for treating HIV infection was approved for treating patients with COVID-19 by the Indian Council of Medical Research, India.

Global Research Initiatives And Funding

Pharmaceutical companies and federal governments are increasingly working together in partnerships and collaborations to provide funding and implement incentive programs for the research and development (R&D) of anti-viral drugs. These partnerships provide financial and technical assistance across different clinical development phases to pharmaceutical companies. For instance, in July 2020, pharmaceutical companies like Novavax and Regeneron received $2 billion funding from US federal government to manufacture drugs and vaccine against COVID-19. The Bill and Melinda Gates foundation with recipients including WHO, drug companies and governments together funded $125 million for drug development against COVID-19.

Opportunities And Recommendations In The Anti-Viral Drug Therapy Market

Opportunities – The top opportunities in the anti-viral drug therapy market segmented by drug class will arise in the reverse transcriptase inhibitors market segment, which will gain $24,880.4 million of global annual sales by 2023. The top opportunities in the anti-viral drug therapy market segmented by application will arise in the HIV segment, which will gain $ 10,038.8 million of global annual sales by 2023.  

Recommendation – To take advantage of the opportunities, the business research company recommends the anti-viral drug therapy companies to focus on combination drug therapies, invest in 3D bioprinting technology, focus on R&D investments and research collaborations, focus on increasing production temporarily during the covid-19 pandemic, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, provide premium pricing for branded drugs, focus on increasing awareness on importance of healthcare, advising asthmatics to use preventive medication to protect against covid-19, focus on educating the people on vaccines and focus on developing generics drugs.

Anti-Viral Drug Therapy Market Segmentation

The anti-viral drug therapy market is segmented by drug class and application.
By Drug Class The anti-viral drug therapy market can be segmented by drug class into
    • a. DNA (Nucleotide) Polymerase Inhibitors
    • b. Reverse Transcriptase Inhibitors
    • c. Protease Inhibitors
    • d. Neuraminidase Inhibitors
    • e. Others
Reverse transcriptase inhibitors market was the largest segment of the anti-viral drug therapy market segmented by drug class, accounting for 50.0% of the total in 2019. Also, it is expected to be the fastest growing segment in the anti-viral drug therapy market segmented by drug class, at a CAGR of 20.0% during 2019-2023.
By Application The anti-viral drug therapy market can be segmented by application into
    • a. HIV
    • b. Hepatitis
    • c. Herpes
    • d. Influenza
    • e. Others
The HIV market was the largest segment of the anti-viral drug therapy market segmented by application, accounting for 34.1% of the total in 2019. Going forward, the influenza segment is expected to be the fastest growing segment in the anti-viral drug therapy market segmented by application, at a CAGR of 14.5% during 2019-2023.
By Geography- The anti-viral drug therapy is segmented by geography into
    • o Asia Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • South Korea
    • o Western Europe
      • France
      • Germany
      • UK
    • o Eastern Europe
      • Russia
    • o North America
      • USA
    • o South America
      • Brazil
    • o Middle East
    • o Africa
North America was the largest region in the global anti-viral drug therapy market, accounting for 50.6% of the total in 2019. It was followed by Asia Pacific and Western Europe, and then the other regions. Going forward, the fastest-growing regions in the anti-viral drug therapy market will be Asia Pacific and Africa, where growth will be at CAGRs of 14.7% and 13.8% respectively. These will be followed by Middle East and North America, where the markets are expected to grow at CAGRs of 13.7% and 12.3% respectively.

Anti-Viral Drug Therapy Competitive Landscape

Major Competitors are:
    • • Gilead Sciences Inc
    • • GlaxoSmithKline plc
    • • Johnson & Johnson
    • • AbbVie Inc.
    • • Merck & Co., Inc.

Other Competitors Include:

    • • Bristol-Myers-Squibb
    • • Boehringer Ingelheim
    • • Aurobindo Pharma
    • • Dr. Reddy’s Laboratories Ltd
    • • Cipla Inc
    • • Hanmi Pharmaceutical
    • • KYORIN Holdings, Inc.
    • • Daewoong Pharmaceutical Co.,Ltd
    • • Shanghai Pharmaceuticals
    • • Fosun Pharma
    • • Yangtze River Pharmaceutical Group
    • • Jiangsu Hengrui Medicine Co., Ltd
    • • Harbin Pharmaceutical Group
    • • Xian-Janssen Pharmaceutical Ltd
    • • Sinopharm Group
    • • Shanghai Acebright Pharmaceuticals Group Co., Ltd.
    • • Guangzhou Pharmaceutical Company Limited
    • • China Meheco
    • • CSPC Pharmaceutical
    • • Sun Pharma
    • • Lupin Limited
    • • Zydus Cadila
    • • Intas Pharmaceuticals
    • • Strides Pharma
    • • Divis Laboratories
    • • Alkem Laboratories
    • • Glenmark Pharmaceuticals
    • • Takeda Pharmaceutical Company
    • • Otsuka Pharmaceutical
    • • Daiichi Sankyo
    • • Nichi-Iko Pharmaceutical Co., Ltd
    • • Chugai Pharmaceutical Co.
    • • Astellas Pharma
    • • Mitsubishi Tanabe Pharma
    • • Sumitomo Dainippon Pharma
    • • Eisai
    • • Shionogi Co.Ltd.
    • • Teva UK Limited
    • • AstraZeneca
    • • Abbott Laboratories
    • • Vectura Group
    • • Novartis AG
    • • Roche Holding AG
    • • Pfizer
    • • Hikma Pharmaceuticals
    • • Sanofi
    • • Pharmstandard
    • • Pharmasyntez
    • • R-Pharm
    • • Alium
    • • ChemRar Group
    • • Servier
    • • Johnson & Johnson
    • • Novo Nordisk
    • • BioCryst Pharmaceuticals Inc.
    • • Selva Therapeutics
    • • Atea Pharmaceuticals
    • • Emergent BioSolutions
    • • Apotex
    • • EMS Pharma
    • • Hypermarcas
    • • Medley
    • • Ache
    • • Eurofarma
    • • Teuto Brasileiro
    • • Biolab Farmaceutica
    • • Cristalia
    • • Libbs
    • • União Quimica
    • • Saudi Pharmaceutical Industries
    • • Medical Appliances Corporation (SPIMACO)
    • • Gulf Pharmaceutical Industries (Julphar)
    • • Mylan Laboratories
    • • BMS
    • • Ascedis Health

    Table Of Contents

  1. 1. Anti-Viral Drug Therapy Market Executive Summary
  2. 2. Table of Contents
  3. 3. List of Figures
  4. 4. List of Tables
  5. 5. Report Structure
  6. 6. Introduction
    • 6.1.1. Segmentation By Geography
    • 6.1.2. Segmentation By Drug Class
    • 6.1.3. Segmentation By Application
  7. 7. Anti-Viral Drug Therapy Market Characteristics
    • 7.1. Market Definition
    • 7.2. Market Segmentation By Drug Class
      • 7.2.1. DNA (Nucleotide) Polymerase Inhibitors
      • 7.2.2. Reverse Transcriptase Inhibitors
      • 7.2.3. Protease Inhibitors
      • 7.2.4. Neuraminidase Inhibitors
      • 7.2.5. Others
    • 7.3. Market Segmentation By Application
      • 7.3.1. HIV
      • 7.3.2. Hepatitis
      • 7.3.3. Herpes
      • 7.3.4. Influenza
      • 7.3.5. Others
  8. 8. Anti-Viral Drug Therapy Market Trends And Strategies
    • 8.1. Combination Drug Therapy For Viral Diseases
    • 8.2. Strategic Collaborations And Agreements
    • 8.3. Global Research Initiatives And Funding
    • 8.4. 3D Bioprinting Technology
    • 8.5. Increasing Number Of Pipeline Studies And Drug Development
  9. 9. Impact Of COVID-19 On Anti-Viral Drug Therapy Market
    • 9.1. Background
    • 9.2. Drug Therapies
    • 9.3. Antiviral Remdesivir Market Growth
  10. 10. Global Anti-Viral Drug Therapy Market Size And Growth
    • 10.1. Market Size
    • 10.2. Historic Market Growth, 2015 – 2019, Value ($ Million)
      • 10.2.1. Drivers Of The Market 2015 – 2019
      • 10.2.2. Restraints On The Market 2015 – 2019
    • 10.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
      • 10.3.1. Drivers Of The Market 2019 – 2023
      • 10.3.2. Restraints On The Market 2019 – 2023
  11. 11. Anti-Viral Drug Therapy Market, Regional And Country Analysis
    • 11.1. Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 11.2. Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Billion)
  12. 12. Global Anti-Viral Drug Therapy Market Segmentation
    • 12.1. Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 12.2. Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  13. 13. Asia-Pacific Anti-Viral Drug Therapy Market
    • 13.1. Asia Pacific Anti-Viral Drug Therapy Market Overview
      • 13.1.1. Region Information
      • 13.1.2. Market Information
      • 13.1.3. COVID-19 Impact
      • 13.1.4. Background Information
      • 13.1.5. Government Initiatives
      • 13.1.6. Regulations
      • 13.1.7. Regulatory Bodies
      • 13.1.8. Major Associations
      • 13.1.9. Taxes levied
      • 13.1.10. Corporate Tax Structure
      • 13.1.11. Investments
      • 13.1.12. Major Companies
    • 13.2. Asia-Pacific Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.3. Asia-Pacific Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.4. Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 13.5. Asia-Pacific Anti-Viral Drug Therapy Market: Country Analysis
    • 13.6. China Anti-Viral Drug Therapy Market
    • 13.7. China Anti-Viral Drug Therapy Market Overview
      • 13.7.1. Country Information
      • 13.7.2. Market Information
      • 13.7.3. COVID-19 Impact
      • 13.7.4. Background Information
      • 13.7.5. Government Initiatives
      • 13.7.6. Regulations
      • 13.7.7. Regulatory Bodies
      • 13.7.8. Major Associations
      • 13.7.9. Taxes levied
      • 13.7.10. Corporate Tax Structure
      • 13.7.11. Investments
      • 13.7.12. Major Companies
    • 13.8. China Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.9. China Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.10. China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 13.11. Australia Anti-Viral Drug Therapy Market
    • 13.12. Australia Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.13. Australia Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.14. Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 13.15. India Anti-Viral Drug Therapy Market
    • 13.16. India Anti-Viral Drug Therapy Market Overview
      • 13.16.1. Country Information
      • 13.16.2. Market Information
      • 13.16.3. COVID-19 Impact
      • 13.16.4. Background Information
      • 13.16.5. Government Initiatives
      • 13.16.6. Regulations
      • 13.16.7. Regulatory Bodies
      • 13.16.8. Major Associations
      • 13.16.9. Taxes levied
      • 13.16.10. Corporate Tax Structure
      • 13.16.11. Investments
      • 13.16.12. Major Companies
    • 13.17. India Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.18. India Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.19. India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 13.20. Indonesia Anti-Viral Drug Therapy Market
    • 13.21. Indonesia Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.22. Indonesia Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.23. Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 13.24. Japan Anti-Viral Drug Therapy Market
    • 13.25. Japan Anti-Viral Drug Therapy Market Overview
      • 13.25.1. Country Information
      • 13.25.2. Market Information
      • 13.25.3. COVID-19 Impact
      • 13.25.4. Background Information
      • 13.25.5. Government Initiatives
      • 13.25.6. Regulations
      • 13.25.7. Regulatory Bodies
      • 13.25.8. Major Associations
      • 13.25.9. Taxes levied
      • 13.25.10. Corporate Tax Structure
      • 13.25.11. Investments
      • 13.25.12. Major Companies
    • 13.26. Japan Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.27. Japan Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.28. Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 13.29. South Korea Anti-Viral Drug Therapy Market
    • 13.30. South Korea Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 13.31. South Korea Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 13.32. South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  14. 14. Western Europe Anti-Viral Drug Therapy Market
    • 14.1. Western Europe Anti-Viral Drug Therapy Market Overview
      • 14.1.1. Region Information
      • 14.1.2. Market Information
      • 14.1.3. COVID-19 Impact
      • 14.1.4. Background Information
      • 14.1.5. Government Initiatives
      • 14.1.6. Regulations
      • 14.1.7. Regulatory Bodies
      • 14.1.8. Major Associations
      • 14.1.9. Taxes levied
      • 14.1.10. Corporate Tax Structure
      • 14.1.11. Investments
      • 14.1.12. Major Companies
    • 14.2. Western Europe Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 14.3. Western Europe Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 14.4. Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 14.5. Western Europe Anti-Viral Drug Therapy Market: Country Analysis
    • 14.6. UK Anti-Viral Drug Therapy Market
    • 14.7. UK Anti-Viral Drug Therapy Market Overview
      • 14.7.1. Country Information
      • 14.7.2. Market Information
      • 14.7.3. COVID-19 Impact
      • 14.7.4. Background Information
      • 14.7.5. Government Initiatives
      • 14.7.6. Regulations
      • 14.7.7. Regulatory Bodies
      • 14.7.8. Major Associations
      • 14.7.9. Taxes levied
      • 14.7.10. Corporate Tax Structure
      • 14.7.11. Investments
      • 14.7.12. Major Companies
    • 14.8. UK Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 14.9. UK Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 14.10. UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 14.11. France Anti-Viral Drug Therapy Market
    • 14.12. France Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 14.13. France Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 14.14. France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 14.15. Germany Anti-Viral Drug Therapy Market
    • 14.16. Germany Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 14.17. Germany Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 14.18. Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  15. 15. Eastern Europe Anti-Viral Drug Therapy Market
    • 15.1. Eastern Europe Anti-Viral Drug Therapy Market Overview
      • 15.1.1. Region Information
      • 15.1.2. Market Information
      • 15.1.3. COVID-19 Impact
      • 15.1.4. Background Information
      • 15.1.5. Government Initiatives
      • 15.1.6. Regulations
      • 15.1.7. Regulatory Bodies
      • 15.1.8. Tax Levied
      • 15.1.9. Associations
      • 15.1.10. Corporate Tax Structure
      • 15.1.11. Investments
      • 15.1.12. Major Companies
    • 15.2. Eastern Europe Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 15.3. Eastern Europe Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 15.4. Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 15.5. Eastern Europe Anti-Viral Drug Therapy Market: Country Analysis
    • 15.6. Russia Anti-Viral Drug Therapy Market
    • 15.7. Russia Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 15.8. Russia Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 15.9. Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  16. 16. North America Anti-Viral Drug Therapy Market
    • 16.1. North America Anti-Viral Drug Therapy Market Overview
      • 16.1.1. Region Information
      • 16.1.2. Market Information
      • 16.1.3. COVID-19 Impact
      • 16.1.4. Background Information
      • 16.1.5. Government Initiatives
      • 16.1.6. Regulations
      • 16.1.7. Regulatory Bodies
      • 16.1.8. Major Associations
      • 16.1.9. Taxes levied
      • 16.1.10. Corporate Tax Structure
      • 16.1.11. Investments
      • 16.1.12. Major Companies
    • 16.2. North America Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 16.3. North America Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 16.4. North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 16.5. North America Anti-Viral Drug Therapy Market: Country Analysis
    • 16.6. USA Anti-Viral Drug Therapy Market
    • 16.7. USA Anti-Viral Drug Therapy Market Overview
      • 16.7.1. Country Information
      • 16.7.2. Market Information
      • 16.7.3. COVID-19 Impact
      • 16.7.4. Background Information
      • 16.7.5. Government Initiatives
      • 16.7.6. Regulations
      • 16.7.7. Regulatory Bodies
      • 16.7.8. Major Associations
      • 16.7.9. Corporate Tax Structure
      • 16.7.10. Investments
      • 16.7.11. Major Companies
    • 16.8. USA Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 16.9. USA Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 16.10. USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  17. 17. South America Anti-Viral Drug Therapy Market
    • 17.1. South America Anti-viral Drug Therapy Market Overview
      • 17.1.1. Region Information
      • 17.1.2. Market Information
      • 17.1.3. COVID-19 Impact
      • 17.1.4. Background Information
      • 17.1.5. Government Initiatives
      • 17.1.6. Regulations
      • 17.1.7. Regulatory Bodies
      • 17.1.8. Tax Levied
      • 17.1.9. Associations
      • 17.1.10. Corporate Tax Structure
      • 17.1.11. Investments
      • 17.1.12. Major Companies
    • 17.2. South America Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 17.3. South America Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 17.4. South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
    • 17.5. South America Anti-Viral Drug Therapy Market: Country Analysis
    • 17.6. Brazil Anti-Viral Drug Therapy Market
    • 17.7. Brazil Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 17.8. Brazil Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 17.9. Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  18. 18. Middle East Anti-Viral Drug Therapy Market
    • 18.1. Middle East Anti-Viral Drug Therapy Market Overview
      • 18.1.1. Region Information
      • 18.1.2. Market Information
      • 18.1.3. COVID-19 Impact
      • 18.1.4. Background Information
      • 18.1.5. Government Initiatives
      • 18.1.6. Regulations
      • 18.1.7. Major Associations
      • 18.1.8. Taxes Levied
      • 18.1.9. Corporate Tax Structure
      • 18.1.10. Investment
      • 18.1.11. Major Companies
    • 18.2. Middle East Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 18.3. Middle East Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 18.4. Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  19. 19. Africa Anti-Viral Drug Therapy Market
    • 19.1. Africa Anti-Viral Drug Therapy Market Overview
      • 19.1.1. Region Information
      • 19.1.2. Market Information
      • 19.1.3. COVID-19 Impact
      • 19.1.4. Background Information
      • 19.1.5. Government Initiatives
      • 19.1.6. Regulations
      • 19.1.7. Regulatory Bodies
      • 19.1.8. Taxes Levied
      • 19.1.9. Corporate Tax Structure
      • 19.1.10. Investments
      • 19.1.11. Corporate Tax Structure
      • 19.1.12. Major Companies
    • 19.2. Africa Anti-Viral Drug Therapy Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
    • 19.3. Africa Anti-Viral Drug Therapy Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
    • 19.4. Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
  20. 20. Global Anti-Viral Drug Therapy Market Competitive Landscape
    • 20.1. Company Profiles
    • 20.2. Gilead Sciences Inc
      • 20.2.1. Company Overview
      • 20.2.2. Products And Services
      • 20.2.3. Business Strategy
      • 20.2.4. Financial Overview
    • 20.3. GlaxoSmithKline plc
      • 20.3.1. Company Overview
      • 20.3.2. Products And Services
      • 20.3.3. Business Strategy
      • 20.3.4. Financial Overview
    • 20.4. Johnson & Johnson
      • 20.4.1. Company Overview
      • 20.4.2. Products And Services
      • 20.4.3. Business Strategy
      • 20.4.4. Financial Overview
    • 20.5. AbbVie Inc.
      • 20.5.1. Company Overview
      • 20.5.2. Products And Services
      • 20.5.3. Business Strategy
      • 20.5.4. Financial overview
    • 20.6. Merck & Co., Inc.
      • 20.6.1. Company Overview
      • 20.6.2. Products And Services
      • 20.6.3. Business Strategy
      • 20.6.4. Financial Overview
  21. 21. Anti-Viral Drug Therapy Market, Key Mergers And Acquisitions
    • 21.1. Merck and Ridgeback Bio Collaborate
    • 21.2. Gilead Acquired Three Antiviral Portfolios From Novartis
    • 21.3. Johnson & Johnson Acquired Novira Therapeutics, Inc.
    • 21.4. Johnson & Johnson Acquired Alios
  22. 22. Anti-Viral Drug Therapy Market Future Outlook and Potential Analysis
    • 22.1. Global Anti-Viral Drug Therapy Market In 2023 – Countries Offering Most New Opportunities
    • 22.2. Global Anti-Viral Drug Therapy Market In 2023 – Segments Offering Most New Opportunities
    • 22.3. Global Anti-Viral Drug Therapy Market In 2023 – Growth Strategies
      • 22.3.1. Market Trend Based Strategies
      • 22.3.2. Competitor Strategies
  23. 23. Anti-Viral Drug Therapy Market, Conclusions And Recommendations
    • 23.1. Conclusions
    • 23.2. Recommendations
      • 23.2.1. Product
      • 23.2.2. Place
      • 23.2.3. Price
      • 23.2.4. Promotion
      • 23.2.5. People
  24. 24. Appendix
    • 24.1. Market Data Sources
    • 24.2. Research Methodology
    • 24.3. Currencies
    • 24.4. Research Inquiries
    • 24.5. The Business Research Company
    • 24.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 2: Global Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 3: Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 4: Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 5: Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 6: Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 8: Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 9: Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 10: Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 11:  Asia Pacific Population By Age Group, 2015-2023, Thousands
  • Table 12: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 13: Asia Pacific GDP Per Capita, 2015-2019, $
  • Table 14: Asia Pacific HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 15: Asia Pacific Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 16: Asia Pacific Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 17: Asia Pacific Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 18: Asia-Pacific Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 19: Asia-Pacific Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 20: Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 21: Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 22:  China Population By Age Group, 2015-2023, Thousands
  • Table 23: China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 24: China GDP Per Capita, 2015-2019, $
  • Table 25: China HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 26: China Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 27: China Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 28: China Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 29: China Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 30: China Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 31: China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 32: China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 33: Australia Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 34: Australia Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 35: Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 36: Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 37:  India Population By Age Group, 2015-2023, Thousands
  • Table 38: India Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 39: India GDP Per Capita, 2015-2019, $
  • Table 40: India HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 41: India Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 42: India Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 43: India Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 44: India Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 45: India Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 46: India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 47: India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 48: Indonesia Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 49: Indonesia Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 50: Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 51: Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 52:  Japan Population By Age Group, 2015-2023, Thousands
  • Table 53: Japan Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 54: Japan GDP Per Capita, 2015-2019, $
  • Table 55: Japan HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 56: Japan Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 57: Japan Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 58: Japan Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 59: Japan Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 60: Japan Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 61: Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 62: Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 63: South Korea Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 64: South Korea Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 65: South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 66: South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 67:  Western Europe Population By Age Group, 2015-2023, Thousands
  • Table 68: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 69: Western Europe GDP Per Capita, 2015-2019, $
  • Table 70: Western Europe HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 71: Western Europe Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 72: Western Europe Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 73: Western Europe Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 74: Western Europe Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 75: Western Europe Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 76: Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 77: Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 78:  UK Population By Age Group, 2015-2023, Thousands
  • Table 79: UK Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 80: UK GDP Per Capita, 2015-2019, $
  • Table 81: UK HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 82: UK Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 83: UK Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 84: UK Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 85: UK anti-viral drug therapy market, Historic, 2015 – 2019, $ Million
  • Table 86: UK Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 87: UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 88: UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 89: France Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 90: France Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 91: France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 92: France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 93: Germany Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 94: Germany Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 95: Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 96: Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 97:  Eastern Europe Population By Age Group, 2015-2023, Thousands
  • Table 98: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 99: Eastern Europe GDP Per Capita, 2015-2019, $
  • Table 100: Eastern Europe HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 101: Eastern Europe Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 102: Eastern Europe Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 103: Eastern Europe Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 104: Eastern Europe Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 105: Eastern Europe Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 106: Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 107: Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 108: Russia Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 109: Russia Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 110: Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 111: Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 112:  North America Population By Age Group, 2015-2023, Thousands
  • Table 113: North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 114: North America GDP Per Capita, 2015-2019, $
  • Table 115: North America HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 116: North America Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 117: North America Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 118: North America Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 119: North America Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 120: North America Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 121: North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 122: North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 123:  USA Respiratory Masks (N95 Respirators, Surgical Masks, And Others) Market, Population By Age Group, 2015-2023, Thousands
  • Table 124: USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 125: USA GDP Per Capita, 2015-2019, $
  • Table 126: USA HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 127: USA Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 128: USA Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 129: USA Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 130: USA Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 131: USA Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 132: USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 133: USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 134:  South America Population By Age Group, 2015-2023, Thousands
  • Table 135: South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 136: South America GDP Per Capita, 2015-2019, $
  • Table 137: South America HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 138: South America Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 139: South America Herpes Disease Prevalence, 2015-2019, Number Of Patients
  • Table 140: South America Influenza Disease Prevalence, 2015-2019, Number Of Patients
  • Table 141: South America Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 142: South America Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 143: South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 144: South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 145: Brazil Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 146: Brazil Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023,  2025F, 2030F, $ Million
  • Table 147: Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 148: Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 149:  Middle East Population By Age Group, 2015-2023, Thousands
  • Table 150: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 151: Middle East GDP Per Capita, 2015-2019, $
  • Table 152: Middle East HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 153: Middle East Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 154: Middle East Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 155: Middle East Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 156: Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 157: Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 158:  Africa Population By Age Group, 2015-2023, Thousands
  • Table 159: Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 160: Africa GDP Per Capita, 2015-2019, $
  • Table 161: Africa HIV Disease Prevalence, 2015-2019, Number Of Patients
  • Table 162: Africa Hepatitis Disease Prevalence, 2015-2019, Number Of Patients
  • Table 163: Africa Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Table 164: Africa Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 165: Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 166: Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 167: Global Anti-Viral Drug Therapy Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 168: Gilead Sciences Inc – Financial Performance, 2015 – 2019, $ Billion
  • Table 169: GlaxoSmithKline plc – Financial Performance, 2015 – 2019, $ Billion
  • Table 170: Johnson & Johnson (J&J) – Financial Performance, 2015 – 2019, $ Billion
  • Table 171: AbbVie Inc – Financial Performance, 2015 – 2019, $ Billion
  • Table 172: Merck & Co. – Financial Performance, 2015-2019, $ Billion
  • Table 173: Global Anti-Viral Drug Therapy Market Size Gain ($ Million), 2019 – 2023, By Country
  • Table 174: Global Anti-Viral Drug Therapy Market Size Gain ($ Million), Segmentation By Drug Class, 2019 – 2023
  • Table 175: Global Anti-Viral Drug Therapy Market Size Gain ($ Million), Segmentation By Application, 2019 – 2023
  • Table 176:  Anti- Viral Drug Therapy- Market Data Sources

List Of Figures

    Figure 1: Global Anti-Viral Drug Therapy Market Segmentation By Drug Class
  • Figure 2: Global Anti-Viral Drug Therapy Market Segmentation By Application
  • Figure 3: Global Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 4: Global Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 5: Global Anti-Viral Drug Therapy Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 6: Global Anti-Viral Drug Therapy Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 7: Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 8: Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 9: Asia-Pacific Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 10: Asia-Pacific Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 11: Asia-Pacific Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 12: China Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 13: China Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 14: China Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 15: Australia Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 16: Australia Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 17: Australia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 18: India Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 19: India Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 20: India Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 21: Indonesia Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 22: Indonesia Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 23: Indonesia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 24: Japan Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 25: Japan Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 26: Japan Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 27: South Korea Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 28: South Korea Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 29: South Korea Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 30: Western Europe Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 31: Western Europe Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 32: Western Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 33: UK Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 34: UK Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 35: UK Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 36: France Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 37: France Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 38: France Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 39: Germany Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 40: Germany Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 41: Germany Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 42: Eastern Europe Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 43: Eastern Europe Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 44: Eastern Europe Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 45: Russia Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 46: Russia Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 47: Russia Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 48: North America Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 49: North America Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 50: North America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 51: USA Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 52: USA Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 53: USA Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 54: South America Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 55: South America Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 56: South America Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 57: Brazil Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 58: Brazil Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 59: Brazil Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 60: Middle East Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 61: Middle East Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 62: Middle East Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 63: Africa Anti-Viral Drug Therapy Market, Historic, 2015 – 2019, $ Million
  • Figure 64: Africa Anti-Viral Drug Therapy Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 65: Africa Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 66: Global Anti-Viral Drug Therapy Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 67: Gilead Sciences Inc – Financial Performance, 2015 – 2019, $ Billion
  • Figure 68: GlaxoSmithKline plc – Financial Performance, 2015 – 2019, $ Billion
  • Figure 69: Johnson & Johnson (J&J) – Financial Performance, 2015 – 2019, $ Billion
  • Figure 70 AbbVie Inc – Financial Performance, 2015 – 2019, $ Billion
  • Figure 71: Merck & Co. – Financial Performance, 2015-2019, $ Billion
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the anti-viral drug therapy market?

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. request a sample here

How will the anti-viral drug therapy market drivers and restraints affect anti-viral drug therapy market dynamics? What forces will shape the anti-viral drug therapy industry going forward?

The anti-viral drug therapy market growth is aided by developments in drug discovery procedures. However, some anti-viral drug therapy market restraints include supply shortages of anti-viral drugs. request a sample here

What is the forecast market size of the anti-viral drug therapy market?

The anti-viral drug therapy market forecast is expected to reach $130,125.3 million in 2030 at a compound annual growth rate of 8.3%. request a sample here

How is the anti-viral drug therapy market segmented?

The global anti-viral drug therapy market is segmented-
a) By Drug Class
b) By Application
request a sample here

Which region has largest share, and what is the market size and growth by geography according to the anti-viral drug therapy global market report?

For more detail on this, request a sample here.

Who are the key players of the global anti-viral drug therapy market?

Top competitors in the global anti-viral drug therapy market are Gilead Sciences Inc; GlaxoSmithKline plc; Johnson & Johnson; AbbVie Inc; Merck & Co., Inc. request a sample here.

What are the key trends in the global anti-viral drug therapy market?

Major trends global anti-viral drug therapy market include combination drug therapy for viral diseases. request a sample here.

What are the major opportunities in the anti-viral drug therapy market and the approaches companies can take to take advantage of them?

For this and further detailed insights on the market, request a sample here. request a sample here.

How does the anti-viral drug therapy market relate to the overall economy and other similar markets?